Publications by authors named "V Nieddu"
In ovarian tumors, the omental microenvironment profoundly influences the behavior of cancer cells and sustains the acquisition of stem-like traits, with major impacts on tumor aggressiveness and relapse. Here, we leverage a patient-derived platform of organotypic cultures to study the crosstalk between the tumor microenvironment and ovarian cancer stem cells. We discovered that the pro-tumorigenic transcription factor FOXM1 is specifically induced by the microenvironment in ovarian cancer stem cells, through activation of FAK/YAP signaling.
View Article and Find Full Text PDFOvarian cancer (OC) displays the highest mortality among gynecological tumors, mainly due to early peritoneal dissemination, the high frequency of tumor relapse following primary debulking, and the development of chemoresistance. All these events are thought to be initiated and sustained by a subpopulation of neoplastic cells, termed ovarian cancer stem cells (OCSC), that are endowed with self-renewing and tumor-initiating properties. This implies that interfering with OCSC function should offer novel therapeutic perspectives to defeat OC progression.
View Article and Find Full Text PDFArticle Synopsis
- Recent research has focused on molecules that can modulate β-adrenergic signaling, highlighting their potential for therapeutic applications, particularly in cancer treatment.
- Despite progress in drug discovery, finding selective β-adrenergic receptor (β-AR) ligands remains difficult due to the complex nature of these receptors and the need for specificity.
- The study synthesized a series of compounds based on a specific chemical scaffold, which helped uncover important structural features that influence their effectiveness and selectivity for different β-AR subtypes, potentially aiding in targeted drug development.
Adenoid cystic carcinoma (ACC) is a rare cancer that preferentially occurs in the head and neck, breast, as well as in other sites. It is an aggressive cancer with high rates of recurrence and distant metastasis. Patients with advanced disease are generally incurable due to the lack of effective systemic therapies.
View Article and Find Full Text PDFThe MYC family of transcription factors is a major driver of human cancer and potential therapeutic target. However, no clinically viable drugs have been yet developed that are able to directly tackle MYC oncoproteins. In our laboratory, we are exploring alternative approaches aiming to disturb signalling downstream of MYC.
View Article and Find Full Text PDF